Is Smoking History the Truly Best Biomarker for Immune Checkpoint Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer?

ESMO Open - United Kingdom
doi 10.1136/esmoopen-2018-000421
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

Immune Checkpoint Modulation for Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2015English

Afatinib Treatment in Advanced Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2011English

Is Immune Checkpoint Inhibition Part of Standard Therapy for Stage III Non-Small Cell Lung Cancer?

Cancer
Cancer ResearchOncology
2018English

High Mortality and Poor Treatment Efficacy of Immune Checkpoint Inhibitors in Patients With Severe Grade Checkpoint Inhibitor Pneumonitis in Non‐small Cell Lung Cancer

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Amplifying Outcomes: Checkpoint Inhibitor Combinations in First‐Line Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

P3.01-19 Sequencing of Ramucirumab+Docetaxel Post-Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Effect of Sex on the Efficacy of Patients Receiving Immune Checkpoint Inhibitors in Advanced Non‐small Cell Lung Cancer

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy